KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oscar Health (OSCR) Total Non-Current Liabilities (2020 - 2025)

Oscar Health (OSCR) has disclosed Total Non-Current Liabilities for 6 consecutive years, with -$1.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 127.36% year-over-year to -$1.0 billion, compared with a TTM value of -$1.0 billion through Dec 2025, down 127.36%, and an annual FY2025 reading of -$1.0 billion, down 127.36% over the prior year.
  • Total Non-Current Liabilities was -$1.0 billion for Q4 2025 at Oscar Health, down from $4.7 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $6.3 billion in Q2 2025 and bottomed at -$1.0 billion in Q4 2025.
  • Average Total Non-Current Liabilities over 5 years is $3.0 billion, with a median of $3.3 billion recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 334.93% in 2024, then plummeted 127.36% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $1.9 billion in 2021, then soared by 92.3% to $3.6 billion in 2022, then fell by 23.42% to $2.7 billion in 2023, then soared by 37.94% to $3.8 billion in 2024, then plummeted by 127.36% to -$1.0 billion in 2025.
  • Business Quant data shows Total Non-Current Liabilities for OSCR at -$1.0 billion in Q4 2025, $4.7 billion in Q3 2025, and $6.3 billion in Q2 2025.